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ABSTRACT 
CHARACTERIZATION OF ANTIBODIES FOR OSTEOPONTIN 
FRAGMENTS IN RHEUMATOID ARTHRITIS 
by Shadi Sharif 
The pro-inflammatory cytokine osteopontin (OPN) is present in rheumatoid 
arthritis (RA) synovial fluid. Osteopontin can be cleaved by thrombin (OPN-R) exposing 
a cryptic a4pi / OC9P1 integrin-binding motif (SVVYGLR). The C-terminal arginine in 
thrombin-cleaved OPN can be further cleaved by plasma carboxypeptidase B (CPB) 
abrogating thrombin-cleaved OPN's binding to the integrins (OPN-L). Specificity of 
antibodies against OPN-R and OPN-L were determined by Western blot and peptide 
blocking studies. Epitope mapping of antibodies revealed Anti-OPN-R and Anti-OPN-L 
recognize the bold amino acids from SVVYGLR and SWYGL respectively. Anti-
OPN-R and Anti-OPN-L ELISA were developed with sensitivity of 0.6 ng/ml. 
Significantly elevated OPN-R and OPN-L levels were detected from rheumatoid arthritis 
synovial fluids compared to osteoarthritis (OA) and psoriatic arthritis (PsA). 
Furthermore, preferential adherence of fibroblast-like synoviocytes from joints to OPN-R 
rather than OPN-L, suggests thrombin-cleaved OPN may play a role in pathogenesis of 
RA which in turn is being regulated by CPB. 
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Introduction 
Osteopontin is a highly glycosylated serine/threonine phosphoprotein found in 
plasma and in extracellular matrix. It functions as a pro-inflammatory cytokine at sites of 
inflammation and is also implicated in bone remodeling (1, 2). OPN is expressed by 
many different cell types including macrophages, natural killer cells, and activated T 
lymphocytes (3, 4, 5, 6). Recently several groups have shown that there is local 
production of OPN in human rheumatoid arthritic joints (7, 8, 9, 10). 
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune inflammatory 
joint disease with complex pathophysiology. RA is characterized by the infiltration of 
inflammatory cells into the joint space leading to invasive growth of synovial tissue 
(pannus) and destruction of cartilage and bone (11). Recently, several independent 
groups have suggested that osteopontin plays an essential role in RA (7, 12, 8). 
Osteopontin contains an Arg-Gly-Asp (RGD) sequence (Fig. 1) that mediates its 
binding to multiple integrins including ocvP3 (the vitronectin receptor) on the surface of 
osteoclasts. It also contains a CD44-binding domain for bone matrix interactions 
important in bone remodeling (13). OPN is an inflammatory cytokine that has been 
shown to induce cell attachment (14) and chemotaxis (15) through RGD-dependent 
interactions with different integrins including ocvPi, avP3, ocvPs, OC5P1, asPi (1, 2). 
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FIGURE 1. Important features of human osteopontin. 
Some features of human osteopontin, integrin binding motifs and receptor binding sites 
are depicted. Thrombin cleavage site and the sequential plasma CPB cleavage sites are 
indicated by arrows. 
OPN also has an integrin-binding motif that is only exposed after its cleavage by 
thrombin (Fig. 1 & Fig. 2). This cryptic motif is the short peptide sequence SVVYGLR 
(in human OPN) and SLAYGLR (in mouse OPN) which interacts with a4pi (16, 17, 18) 
and a9Pi integrins (19, 20). a4(3i otherwise known as VLA-4 or CD49d / CD29 is 
expressed on the surface of lymphocytes and smooth muscle cells (16, 17, 18) while agf3i 
is expressed on neutrophils, epithelial cells and smooth muscle cells (19, 20, 21). 
According to both Bayless (17) and Green (18) the interactions of SVVYGLR (located 
on the C-terminal end of the N-terminal thrombin-cleaved OPN fragment) with a4(3i and 
agPi integrins are independent of the RGD motif. 
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FIGURE 2. Generation of OPN-R and OPN-L by sequential cleavage by thrombin and 
plasma carboxypeptidase B. 
The sequence of full-length human osteopontin near its thrombin cleavage site is 
depicted. A, Treatment of OPN with thrombin (Factor Ha) results in generation of OPN-
R and C-terminal fragment. E) Plasma carboxypeptidase B (CPB) removes C-terminal 
arginin from OPN-R to generate OPN-L. 
Recently Yamamoto et al. demonstrated that the cryptic epitope of OPN 
(SLAYGLR) has an essential role in a mouse model of rheumatoid arthritis (12). They 
successfully demonstrated that a blocking antibody against the exposed cryptic epitope of 
OPN in RA inhibited pannus proliferation and infiltration of inflammatory cells, in 
addition to reducing bone erosions in vivo. This finding is direct evidence that in the 
murine model of RA the thrombin-cleaved OPN plays an essential role in progression of 
disease. The thrombin cleavage of OPN is depicted in Figure 2. The existence of 
thrombin-cleaved OPN has also been detected in human rheumatoid arthritis synovial 
fluids by Ohshima et al. using an indirect ELISA method (10). Ohshima et al. compared 
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the binding of an antibody that recognizes intact and cleaved OPN to one that recognizes 
full-length OPN only. Clearly, findings by both Yamamoto et al. and Ohshima et al. 
suggest that thrombin-cleaved form of OPN is important in both human and murine 
model of RA. 
Plasma carboxypeptidase B (CPB), also called thrombin-activatable fibrinolysis 
inhibitor or TAFI, can inactivate thrombin-cleaved OPN adhesion to Jurkat T cells by 
removing the C-terminal arginine from the exposed SVVYGLR epitope (14). Cleavage 
by CPB converts the thrombin-cleaved OPN (OPN-R) into the inactive des-arg form 
(OPN-L) (Fig. 2). Both thrombin and CPB are generated locally within the joint space in 
RA (22). Therefore, one may hypothesize that CPB regulates the inflammatory role of 
thrombin-cleaved OPN in RA. 
In order to investigate the specific inflammatory role of thrombin-cleaved OPN 
(OPN-R) in RA and its regulation by CPB, I have characterized two antibodies and 
determined their sensitivity and specificity for their respective antigens, OPN-R and 
OPN-L. I have also developed specific sandwich ELISA for direct detection of OPN-R 
and OPN-L from biological fluids, and investigated the levels of OPN-R and OPN-L in 
rheumatoid arthritis in comparison to osteoarthritis (OA) and psoriatic arthritis (PsA). 
Furthermore, to explore the functional role of OPN-R in RA, I have demonstrated that 
fibroblast-like synoviocytes lining the inflamed joints of RA patients, which express 0C4 
integrin, bind preferentially to OPN-R. 
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Materials and Methods 
Reagents 
Human OPN Quantikine ELISA kit was purchased from R&D Systems 
(Minneapolis, MN). Goat anti-rabbit HRP-labeled antibody conjugate was from Jackson 
Immunological (West Grove, PA). Heteroblock was purchased from Omega Biologicals 
(Bozeman, MT). Human thrombin was obtained from Haematologic Technologies 
(Essex Junction, VA), while CPB was from ACTICHROME CPB activity kit purchased 
from American Diagnostica (Stamford, CT). The peptides SLAYGL, SWYGL and 
SLAYGLR were synthesized by the peptide synthesis facility at Beckman Center, 
Stanford University School of Medicine. For epitope mapping of antibodies, a series of 
peptides were designed based on the immunogen sequences with introduction of alanine 
in place of each amino acid (Table I). The peptides for Anti-OPN-R (CA1999) and anti-
OPN-L (CA1998) were synthesized at Elim Biopharmaceuticals Inc (Hayward, CA). 
Table I. List of peptides used to map the epitope for Anti-OPN-R andAnti-OPN-L 
Anti-OPN-R Peptides Anti-OPN-L Peptides 
RLGYALS (random peptide) RLGYALS (random peptide) 
SLAYGLR (Anti-OPN-R immunogen) SVVYGL (Anti-OPN-L immunogen) 
SAAYGLR SAVYGL 
SLAYGLR SVAYGL 
SLAAGLR SVVAGL 
SLAYALR SVVYAL 
SLAYGAR SVVYGA 
SLAYGLA SWYGL-NH2 
SLAYGLR-NH2 
To investigate significance of each amino acid within the immunogen sequence, alanine 
was introduced in place of each amino acid (shown in blod), and affinities of the antibodies for 
the mutated peptides were determined as discussed in text. 
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Antibodies 
The antibodies were generated at Berelex Laboratories Incorporated, and were 
kindly donated to Dr. Lawrence Leung's Laboratory at Stanford School of Medicine, 
where this research was conducted. Rabbits were immunized with short peptides from 
the carboxyl termini of human VDTYDRGDSWYGLR (CA2001) for detection of 
OPN-FL; human SVVYGLR (CA1997) and mouse SLAYGLR (CA1999) for detection 
of OPN-R, and carboxyl termini of human SWYGL (CA1998), mouse SLAYGL 
(CA2000) for detection of OPN-L (Table II). 
Table II. List of antibodies and their respective immunogens 
Antibody Name 
Anti-OPN (CA2001) 
Immunogen Antigen 
VDTYDRGDSWYGLR Human OPN-FL, OPN-R, OPN-L 
Anti-OPN-R (CA1999) SLAYGLR (Mouse) 
Anti-OPN-L (CA1998) SVVYGL (Human) 
CA1997 S WYGLR (Human) 
Human & Mouse OPN-R 
Human OPN-L 
Failed to recognize OPN-R Specifically 
Synovial fluid samples 
Archived synovial fluid samples were kindly provided by Dr. Jason J. Song and 
Dr. William H. Robinson. 26 rheumatoid arthritis, 18 osteoarthritis and 10 psoriatic 
arthritis samples were analyzed. Samples were stored at -80°C until use. 
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Human osteopontin purification from milk 
OPN was purified from human milk (Mothers Milk Bank, San Jose, CA) 
according to previously published procedure with minor modifications (17). One liter of 
human milk pooled from several donors was incubated on ice to allow for separation of 
the whey from the curd. The whey was then clarified from the curd by centrifuging at 
23000 x g for 60 min at 4°C, and filtered through a 0.2uM filter unit. ImM benzamidine 
and 2mM DTT were added and the clarified whey was batch adsorbed to Q-sepharose 
resin (GE Healthcare, Pittsburgh, PA) for 2 h at 4°C. Following batch-adsorption, the 
resin was washed with lOmM NaPhosphate pH 7.4, 0.2M NaCl, 2mM DTT, ImM 
benzamidine and the protein was eluted using lOmM Na Phosphate pH 7.4, 1M NaCl, 
2mM DTT, ImM benzamidine. The eluant was dialyzed in lOmM Na Phosphate pH 7.4, 
4M NaCl, 2mM DTT, ImM benzamidine overnight at 4°C, and loaded onto a 5ml HiTrap 
Phenyl Sepharose HP column (GE Healthcare, Pittsburgh, PA) at lml/min. Then, the 
column was washed until OD280 plateaued to a baseline level and a linear gradient from 
4M to 2M NaCl at 1 ml/min was used to elute the proteins. 1ml fractions were collected 
and analyzed by SDS-page. Pure fractions were pooled and dialyzed against PBS pH 7.4. 
Impure fractions were dialyzed against 4M salt and re-applied to the phenyl sepharose 
column until purified. The purified protein was sent out to Stanford University Beckman 
Center for mass spectroscopy analysis and was confirmed as osteopontin (Data not 
shown). 
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Thrombin-cleaved OPN and thrombin / CPB-cleaved OPN preparation 
To generate OPN-R, lOjig of purified milk osteopontin was digested with lOOnM 
of thrombin in presence of 20mM HEPES, ImM CaCl2 , 150mM NaCl, 0.1% PEGgooo, 
pH 7.6 at 37°C. After 2, 5, 10, 20, 30, 40, 50, 60, 75 minutes of incubation with 
thrombin, the reaction was stopped using 200nM of the thrombin inhibitor, PPACK (D-
Phe-Pro-Arg-chloromethyl ketone). 500ng of OPN from each time point was analyzed 
by SDS-PAGE. 60 minutes was determined to be the ideal time for complete conversion 
of OPN to OPN-R. To make OPN-L, the thrombin-cleaved OPN-R was treated with 
lOOnM CPB for 1 h at room temperature. Due to thermal instability of CPB, further 
treatment was not necessary for stopping the reaction. OPN-R and OPN-L were analyzed 
by SDS-PAGE and Western blot to ensure complete cleavage of milk OPN and the 
proteins were aliquoted and stored at -80°C for use as a standard in ELISA. 
Specificity determination of antibodies to OPN-FL, OPN-R and OPN-L by 
Western blot 
2ug of each of the three forms of osteopontin (prepared as described above), were 
incubated with ImM DTT and sample loading buffer (Invitrogen, Carlsbad, CA) at 90°C 
for 15 min and were vortexed. Three identical 10% Nuvex polyacrylamide gel were 
prepared. Per gel, 3 identical sets of protein ladder, lOOng of OPN-F1, OPN-R and OPN-
L were run using MOPS running buffer. The proteins were later transferred onto PVDF 
membranes (BioRad, Hercules, CA). Stained Precision Plus Protein Marker (BioRad, 
Hercules, CA) was used to ensure complete transfer of proteins to PVDF membrane. The 
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blots were incubated in blocking buffer consistent of 50mM Tris-HCL, 2mM CaCL2, 
80mm NaCl, 5% w/v non-fat milk and 0.2% Niodent P40, pH 8.0. Each membrane was 
cut into three pieces, so that each piece contained a stained protein ladder, lOOng of 
OPN-F1, OPN-R, and OPN-L. Membranes were probed with 1 ug/ml of each of the 
antibodies, Anti-OPN, Anti-OPN-R, and Anti-OPN-L (Table II) respectively for 1 h. 
Goat anti-rabbit horse radish preoxidase-linked IgG (Jackson Immunological, West 
Grove, PA) was used as secondary antibody at 1/15000 in blocking buffer for 40 min, 
and developed using ECL reagents (GE Healthcare, Pittsburgh, PA). 
In order to determine the specificity of Anti-OPN-R and Anti-OPN-L antibodirs, 
after incubation with blocking buffer the two blots were each cut into three identical 
pieces, each piece containing a protein ladder, lOOng of OPN-F1, OPN-R and OPN-L. 
Antibodies were pre-incubated with their cognate and non-cognate peptides (SWYGL 
and SLAYGLR) at a molar ratio of 1:50 for 2 h at room temperature before probing the 
membranes. The first three blots from the same gel were incubated for 1 h with Anti-
OPN-R, 1:50 molar ratio of Anti-OPN-R to SLAYGLR (congnate peptide), and 1:50 
molar ratio of Anti-OPN-R to SWYGL (non-cognate peptide) respectively. The second 
set of blots from the same gel were incubated for 1 h with Anti-OPN-L, 1:50 molar ratio 
of Anti-OPN-L to SWYGL (congnate peptide), and 1:50 molar ratio of Anti-OPN-L to 
SLAYGLR (non-cognate peptide) respectively. After incubation with the primary 
antibodies blots were treated as described above. 
Identical 10% Nuvex polyacrylamide gel with lug of each of the three forms of 
OPN was run along with the Western blot gels and was stained with Bio-Safe Coomassie 
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G250 Stain (BioRad, Hercules, CA) to not only prove purity of the purified proteins in 
each lane, but also as positive control for the electrophoresis. 
Development of sandwich ELISAfor detection of human OPN 
To detect OPN-FL from biological samples, a commercial ELISA kit (R&D 
Systems OPN Quantikine ELISA Kit) was used according to the manufacturer's 
instructions. For detection of OPN-R and OPN-L, the commercial R&D Systems OPN 
antibody was used to capture, and Anti-OPN-R and Anti-OPN-L antibodies were used for 
detection respectively. Various concentrations of the three forms of OPN ranging from 
0.625ng/ml to 50ng/ml were incubated in the antibody-coated wells for 2 h at room 
temperature. Wells were washed three times with wash buffer (PBS, 0.05% Tween-20, 
pH 7.4) and were incubated with 0.5 ug/ml of the corresponding antibody for 1 h at room 
temperature. After three washes, goat anti-rabbit HRP-linked antibody was incubated in 
the wells at 1/15000 dilution for 40 min. Then, wells were washed three times and 100 ul 
of substrate (TMB; Alpha Diagnostic, San Antonio, TX) was added to the wells for 15 
min. The reaction was stopped with 100 ul of stop solution (Alpha Diagnostic, San 
Antonio, TX) and read at 450 nm. 
Epitope mapping of Anti-OPN-R and Anti-OPN-L antibodies 
To map the epitopes for Anti-OPN-R and Anti-OPN-L antibodies, the commercial 
R&D Systems OPN antibody was used as the capture antibody. 10 ng/ml of milk OPN-R 
and OPN-L were incubated in the antibody-coated wells. Peptides ALAYGLR, 
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SAAYGLR, SLGYGLR, SLAAGLR, SLAYALR, SLAYGAR, SLAYGLA, SLAYGLR-
NH2 , RLGYALS were used to epitope-map Anti-OPN-R antibodies, and SAVYGL, 
SVAYGL, SWAGL, SVVYAL, SWYGA, SWYGL-NH2, RLGYALS were used for 
Anti-OPN-L antibodies (Table I). Various molar excesses of peptides to antibodies 
(ranging from 1:1 to 50:1, peptide to antibody ratio) were pre-incubated for 2 h at room 
temperature, then were added to the wells and incubated for an additional hour. The 
plates were then washed three times with wash buffer and 1/15000 dilution of goat anti-
rabbit HRP-linked antibody was incubated in the wells for 40 min. Following three 
washes the plates were developed as described in the previous section. 
Detection ofOPN-FL, OPN-R and OPN-Lfrom RA, OA, andPsA synovial fluids 
byELISA 
Synovial joint fluids were thawed on ice and were incubated with 3 ug/ml of 
HeteroBlock (Omega Biologicals, Bozeman, MT) to reduce the chance of cross-linking 
between capture and detection antibodies by rheumatoid factor. Following a 10 min 
centrifugation at 400 x g at 4°C (to clarify the samples), samples were diluted in R&D 
Systems ELISA kit RD1-6 assay diluent. OPN-FL in synovial fluids was detected using 
the R&D Systems commercial assay. OPN-R and OPN-L proteins were measured using 
the sandwich ELISA systems described above. Due to the wide range of OPN levels 
detected (ranging from 1-2 ng/ml to 50 ug/ml), median OPN levels are reported. 
Statistical analysis were performed using the Wilcoxon Rank-Sum (Mann-Whitney) test 
with/? values less than 0.05 being considered significant. 
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Adhesion assay on preferential binding offibroblast-like synoviocytes to OPN-R 
Primary cultured fibroblast-like synoviocytes from RA joints, kindly provided by 
Dr. Robinson, were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 
10% FBS. Recombinant wild type and RGD-mutated human OPN-FL, OPN-R and 
OPN-L (Table III), kindly provided by Dr. Leung, were coated onto 96-well micro black 
fluorescent plates at 500 ng/ml in 0.1M NaHCCb, pH 8.5, and incubated for 2 h at room 
temperature. Wells were washed with PBS and blocked using 2% BSA, 0.05% Tween 
20, PBS pH 7.4 for 1 h. Fibroblast-like synoviocytes were labeled with CFDA cell tracer 
dye (Invitrogen, Carlsbad, Ca) for 30 min at 37°C and washed twice with PBS. The 
OPN-coated wells were washed with PBS and 5000 cells were added per well and 
incubated for 1 h at 37°C. The wells were washed three times with PBS at room 
temperature, and the plate was read at excitation wavelength of 488 nm and emission of 
538 nm using Fluoroskan Ascent (Thermo Scientific, Waltham, MA). Data were 
recorded as relative fluorescence unit (RFU). 
Table III. List of recombinant osteopontin proteins 
Recombinant proteins Sequence near thrombin cleavage site 
OPN-FL Wild Type ...153 VDTYDGRGDSVVYGLRSKSKKFR 175 ... 
OPN-R Wild Type ...153 VDTYDGRGDSVVYGLR 168 
OPN-L Wild Type ...153 VDTYDGRGDSVVYGL 167 
RAA-OPN-FL ...153 VDTYDGRAASWYGLRSKSKKFR 175 ... 
RAA-OPN-R ...153 VDTYDGRAASVVYGLR 168 
RAA-OPN-L ...153 VDTYDGRAASVVYGL 167 
Sequence near the thrombin cleavage site is depicted. RGD has been mutated to RAA in some of 
the proteins as indicated. Vector construction, expression and purification of the proteins were 
performed by Dr. Timothy Myles in Dr. Leung's Laboratory and have been extensively described 
in reference 14. 
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Adhesion assay on preferential binding offibroblast-like synoviocytes to RGDS 
and SWYGLR peptides 
Primary cultured fibroblast-like synoviocytes were maintained as described in the 
previous section. 0, 0.1, 1, 10, 100, 1000 uM RGDS, GRGES, SWYGLR, and 
SWYGL peptides were coated onto 96-well micro black fluorescent plates in 0.1 M 
NaHC03, pH 8.5, and incubated for 2 h at RT. Wells were washed with PBS and 
blocked using PBS, 2% BSA, pH 7.4 for 1 h. Fibroblast-like synoviocytes were labeled 
with CFDA cell tracer dye (Invitrogen, Carlsbad, Ca) for 30 min at 37°C, and washed 
twice with PBS. 5000 cells were added per well and incubated for lh at 37°C. The wells 
were washed three times with PBS at RT and the plates were read at excitation 
wavelength of 488 nm and emission of 538 nm. 
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Results 
Thrombin cleavage of milk osteopontin 
To determine efficiency of thrombin cleavage of milk osteopontin, a time study 
was conducted. lOug of OPN was treated with lOOnM of thrombin. At various time 
points reaction was stopped by 200nM PPACK, and 500ng aliquots of OPN were 
analyzed by SDS-PAGE (Fig. 3). Analysis of the SDS-PAGE revealed disappearance of 
the full-length milk OPN (55KD) and appearance of OPN-R (30KD band) and the 25KD 
C-terminal fragment with increasing time. It is interesting to note that after only 5 
minutes of incubation with lOOnM thrombin the cleaved products are already visible. 
The reaction seemed to have reached completion at 50 minutes. Therefore, to generate 
OPN-R for ELISA calibration curves 1 h was chosen as the ideal incubation time with 
lOOnM of thrombin. 
FIGURE 3. Thrombin time-course of osteopontin cleavage 
Purified milk osteopontin (lOug) was incubated with lOOnM of thrombin at 37°C and at 
various time points the reaction was stopped by PPACK and 500ng of osteopontin (per 
lane) was analyzed by SDS-PAGE. 
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Specificity determination of antibodies Anti-OPN-R and Anti-OPN-L for OPN-R 
and OPN-L respectively by Western blot 
Specificity of antibodies, Anti-OPN-R (CA1999) and Anti-OPN-L (CA1998) 
were tested by Western blot analysis. Anti-OPN (CA2001) recognized all forms of OPN 
(Fig. 44). Anti-OPN-L (CA1998) recognized human OPN-L with high degree of 
specificity (Fig. 44 right panel). The antibody raised against the mouse epitope 
SLAYGLR for detection of OPN-R (CA1999 or Anti-OPN-R) was found to detect both 
the human and mouse version of OPN-R specifically (Table II). The antibody raised 
against the human version of the peptide SVVYGLR although recognized OPN-R was 
not as reactive as the mouse antibody. Therefore, CA1999 was used for detection of 
human OPN-R and CA1998 was used for detection of OPN-L for the remainder of the 
study. The specificity of the two antibodies were further confirmed by using the cognate 
and non-cognate peptides to block the antibody-antigen interactions. The peptide 
SLAYGLR pre-incubated with Anti-OPN-R prior to probing the membrane, blocked 
recognition of OPN-R by Anti-OPN-R (Fig. 48). However, pre-incubation of the Anti-
OPN-R with the non-cognate peptide at the same molar ratio did not block recognition of 
OPN-R by the antibody. Similarly, the peptide SVVYGL pre-incubated with Anti-OPN-
L blocked recognition of OPN-L by Anti-OPN-L, but pre-incubation of the antibody with 
the non-cognate SLAYGLR peptide had no effect on Anti-OPN-L recognition of OPN-L 
(Fig. AC). In this study the focus was on CA1998 (Anti-OPN-L) for detection of human 
OPN-L and CA1999 (Anti-OPN-R) for detection of human OPN-R. 
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FIGURE 4. Specificity of antibodies against OPN determined by Western blot analysis. 
A, Left panel: SDS-PAGE on different forms of OPN. Milk OPN was treated with 
nothing (-), thrombin (Ila) or thrombin/CPB (Ila/CPB) to generate OPN-FL (60kD), 
OPN-R (30KD) and OPN-L (30KD) respectively. A,Right Panel from left to right: 
Western blot analysis of different forms of OPN with CA2001 (for recognition of all 
forms of OPN), CA1999 (Anti-OPN-R), and CA1998 (Anti-OPN-L). B, Specificity of 
Anti-OPN-R. From left to right: blot incubated with Anti-OPN-R only, 1:50 molar ratio 
of Anti-OPN-R to cognate peptide, 1:50 molar ratio of Anti-OPN-R to non-cognate 
peptide. C, Specificity of Anti-OPN-L. From left to right: blot incubated with Anti-OPN-
R, 1:50 molar ratio of Anti-OPN-L to cognate peptide and 1:50 molar ratio of Anti-OPN-
L to non-cognate peptide. 
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Detection of human OPN by specific sandwich ELISA 
The two antibodies, Anti-OPN-R and Anti-OPN-L, were used to develop ELISA 
for detection of human OPN-R and OPN-L from biological fluids. The different forms of 
milk OPN (OPN-FL, OPN-R, OPN-L) were used to construct calibration curves. 
CA2001 antibody although detected the DTT, heat-denatured OPN in Western blot, it 
was unable to recognize the native form of full-length OPN in the ELISA system. 
Therefore, R&D Systems ELISA kit was used to measure the OPN-FL levels according 
to manufacturer instructions. The R&D Systems OPN ELISA kit capture antibody was 
also used for capture of OPN-R and OPN-L. The kit was very sensitive for detection of 
OPN-FL, but not for OPN-R and OPN-L (Fig. 5A). Anti-OPN-R and Anti-OPN-L were 
much more sensitive and specific for detection of the cleaved forms of OPN. Anti-OPN-
R antibodies detected OPN-R, but not OPN-FL or OPN-L (Fig. 5B). Similarly, Anti-
OPN-L antibodies reacted specifically with OPN-L, but not OPN-FL or OPN-R 
(Fig. 5Q. The ELISA detected as low as 0.6 ng/ml of OPN-R and OPN-L using the 
antibodies. To ensure that presence of high level of full-length OPN does not affect the 
detection efficiency of OPN-R and OPN-L, a 20-fold molar excess of intact full-length 
OPN was incubated with either OPN-R or OPN-L in the wells (Fig. 6A&B). Such excess 
did not affect the read-out of the ELISA, signifying that the OPN-R and OPN-L assays 
are appropriate for measuring the cleaved forms of OPN from blood and other biological 
fluids in presence of high levels of intact OPN. 
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FIGURE 5. Development of specific sandwich ELISA for OPN-R and OPN-L 
A, R&D Systems OPN kit is specific for OPN-FL, but not OPN-R and OPN-L. B, 
Development of sandwich ELISA specific for OPN-R. C, Development of sandwich 
ELISA specific for OPN-L. 
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FIGURE 6. OPN-FL does not interfere with OPN-R and OPN-L in sandwich ELISA 
A, OPN-FL does not interfere with OPN-R ELISA. 20 fold molar excess of OPN-FL 
incubated with OPN-R at different concentrations were compared with OPN-R only 
wells, at 20 fold molar excess. B, OPN-FL does not interfere with OPN-L ELISA. 20:1 
ratio of OPN-FL to OPN-L vs. OPN-L only wells, showed non-interference of OPN-FL 
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Epitope mapping ofAnti-OPN-R and Anti-OPN-L antibodies 
To identify the exact epitopes of OPN-R and OPN-L recognized by Anti-OPN-R 
and Anti-OPN-L antibodies respectively, a series of peptides were synthesized based on 
the sequence of peptides used as immunogens for generation of the antibodies (Table II). 
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The cognate peptide for Anti-OPN-R was the mouse sequence SLAYGLR, and 
the peptide used as the immunogen for generation of Anti-OPN-L was SVVYGL. In 
order to identify which amino acids from the peptides are important for interaction with 
the respective antibodies, alanine was introduced in place of each of the amino acids in 
the synthesized peptides (Table I). The peptides were used as competitive inhibitors of 
the antibodies binding to OPN-R and OPN-L in the sandwich ELISA systems. The 
competitive inhibition assay with all peptides were done with increasing molar ratio of 
peptides to antibodies, but the dose dependent-curves are only depicted for the cognate 
and the non-cognate peptides (Fig. 1A&.C). The rest of the peptide blocking experiments 
are only shown at 50:1 molar ratio of peptides to antibodies for convenience 
(Fig. 1B&D). 
For Anti-OPN-R antibodies, pre-incubation of the antibodies with increasing 
molar excess of the peptides SLAYGLR and SWYGLR inhibited the binding of the 
antibodies to OPN-R in a dose-dependent manner (Fig. 1A). However, the peptides 
SLAYGL and SVVYGL did not interfere with binding of Anti-OPN-R antibodies to 
OPN-R coated plate, confirming the C-terminal arginine in the thrombin-cleaved OPN is 
essential for recognition of OPN-R by Anti-OPN-R. The peptides ALAYGLR, 
SAAYGLR, SLGYGLR effectively inhibited the binding of Anti-OPN-R, indicating that 
serine, leucine, and alanine residues of SLAYGLR are not essential for Anti-OPN-R 
recognition (Fig. IB). On the other hand, substitution of alanine for tyrosine, second 
leucine, arginine, and glycine rendered the peptides SLAAGLR, SLAYGAR, 
SLAYGLA, and to some degree SLAYALR ineffective in inhibiting the binding of Anti-
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OPN-R antibodies to OPN-R. This means tyrosine, second leucine, arginine, and to some 
degree glycine in SLAYGLR are involved in defining the epitope for Anti-OPN-R. The 
epitope YGLR is shared by both human and mouse version of thrombin-cleaved OPN, 
which explains why Anti-OPN-R (raised against the mouse epitope SLAYGLR, and not 
the human epitope SVVYGLR), effectively recognizes both human and mouse OPN-R. 
In addition, substituting the C-terminal carboxyl group of arginine by an amide group 
diminished inhibitive effect of the peptide, indicating that the carboxyl group is also 
essential for recognition by Anti-OPN-R. 
For Anti-OPN-L antibodies, the cognate peptide SWYGL effectively blocked 
antibody binding in a dose-dependent manner while the peptide sequence SVVYGLR 
was completely ineffective (Fig. 1C). Furthermore, the blocking studies indicated 
tyrosine, glycine, leucine, the C-terminal carboxyl group, and to a lesser extend the first 
valine in the peptide sequence SWYGL are essential in defining the epitope for Anti-
OPN-L (Fig. ID). The blocking studies showed Anti-OPN-R and Anti-OPN-L 
essentially recognize three to four residues, with the C-terminal residues arginine or 
leucine and their carboxylates being most important for recognition by the specific 
antibodies. 
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FIGURE 7. Epitope mapping of Anti-OPN-R and Anti-OPN-L antibodies by 
competitive ELISA 
A & B, Epitope mapping of Anti-OPN-R antibodies by various peptides. A, Anti-OPN-R 
antibodies recongnition of OPN-R were blocked by pre-incubation of antibodies with 
increasing concentrations of cognate peptides (SLAYGLR and SVVYGLR). B, Anti-
OPN-R inhibition by various peptides at 50:1 molar excess of peptides to antibodies 
signifies the bold underlined epitopes in SLAYGLR are important for recognition of 
OPN-R by Anti-OPN-R. C, Anti-OPN-L antibodies' recongnition of OPN-L were 
blocked by pre-incubation of antibodies with increasing concentration of cognate peptide 
(SVVYGL). D, Anti-OPN-L inhibition by various peptides at 50:1 molar excess of 
peptides to antibodies signifies the bold underlined epitopes in SVVYGL are important 
for recognition of OPN-L by Anti-OPN-L. 
Molar Ratio Peptide to Afltt-OPN-L ^&^^^&A&&J*&-4r 
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Determination ofOPN-Fl, OPN-R and OPN-L levels from synovial fluids ofRA, 
OA, andPsA patients by ELISA 
Previous studies have reported increased OPN levels in synovial fluids from RA 
patients (8, 10). To test whether cleaved forms of OPN are also detectable in the synovial 
fluid samples of RA patients, ELISA systems were developed for detection of cleaved 
forms of OPN. The commercial R&D Systems ELISA kit was used for detection of 
OPN-FL. For comparison of RA synovial fluid OPN levels, synovial fluid samples from 
OA and PsA were used since synovial fluid from healthy joints cannot be obtained. The 
Wilcoxon rank sum test was used to compare the median values of each OPN form 
between the three patient groups. In rheumatoid arthritis patients synovial fluids OPN-
FL (352.5 ng/ml) was significantly elevated compared to their normal plasma level (50 
ng/ml), however, this level did not reach significance when compared to the OPN-FL 
level from OA (157.9 ng/ml, p-value 0.142) and PsA (143.4 ng/ml, p value 0.074) 
synovial fluids (Fig. &4). On the other hand, OPN-R and OPN-L levels were 
significantly higher in RA synovial fluids when compared to OA and PsA. The median 
RA OPN-R level was 138.6 ng/ml compared to a 10.6 ng/ml for OA and 2.2 ng/ml for 
PsA (p value < 0.001), and the median OPN-L level of RA was 205.3 ng/ml compared to 
25.9 ng/ml for OA and undetectable for PsA (p value < 0.006) (Fig. 8A). There was a 
wide range of full-length and cleaved OPN levels in the synovial fluids of RA patients 
compared to OA and PsA, ranging from undetectable to more than 50 ug/ml. Such 
heterogeneity in OPN levels may be due to differences in stage of the disease, the 
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particular treatment in individual patients, or other factors. The median ratio of cleaved 
OPN to total OPN in rheumatoid arthritis synovial fluid was 0.5, indicating that a 
significant amount of OPN exists in its cleaved forms within the rheumatic joint space 
compared to the OA and PsA (Fig. 85). 
FIGURE 8. Comparison of OPN-FL, OPN-R and OPN-L from OA, PsA, and RA 
synovial fluids by ELISA. 
A, Comparison of OPN levels in Osteoarthritis (OA) n=18, psoriatic arthritis (PsA) n=10, 
rheumatoid arthritis (RA) n=26. Bars indicate median values of each disease group. *p 
value < 0.006 by Wilcoxon Ranked Sum test. B, Significantly higher cleaved OPNs 
detected in RA patients' synovial fluids. The ratio of cleaved OPNs (OPN-R plus OPN-
L) to total OPN (sum of the three different OPN forms) for OA, PsA, and RA are 
depicted. * p value < 0.003. 
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Determination of preferential binding offibroblast-like synoviocytes to OPN-R 
To investigate the role of thrombin-cleaved OPN in RA, adhesion of arthritic 
fibroblast-like synoviocytes to different forms of osteopontin was studied. Previously 
described wild type and RGD-mutated recombinant OPN-FL, OPN-R, and OPN-L (14) 
were coated onto a 96-well plate. In the RGD-mutated forms of OPN, the RGD site was 
mutated into RAA in order to distinguish RGD-dependent adhesions (through integrins 
such as avP3) from RGD-independent adhesions. A significant two-fold increase in FLS 
adhesion was seen with wild type OPN-R compared to wild type OPN-FL and OPN-L, 
suggesting the exposure of the cryptic integrin-binding motif SVVYGLR in OPN-R to be 
the reason for the enhanced binding (Fig. 9A). However, in the case of both OPN-F1 
(where the SVVYGLR is sterically-hindered) and OPN-L (where the C-terminal arginine 
has been cleaved off by CPB) the enhanced binding of FLS to OPN is significantly 
diminished. Lack of specific binding to RGD-mutated (RAA) versions of the three forms 
of OPN in comparison with the wild type OPNs suggests that RGD is essential for the 
initial binding of FLS to OPNs. In the absence of the RGD sequence, SVVYGLR alone 
was unable to support binding to a4 integrin subunits (RAA-OPN-R), perhaps due to 
lack of conformational integrity. The magnitude of cell binding was clearly enhanced 
when both RGD and SVVYGLR were present. 
To further investigate whether RGD is essential for adhesion of FLS, various 
amounts of RGDS peptide (ranging from 0.1 to 1000 uM) were coated onto 96-well 
plates and FLS adhesion to RGDS peptide-coated wells were compared to adhesion to 
GRGES peptide (Fig. 92?). As expected, FLS adhered to RGDS peptide in a dose-
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dependent manner. Similarly, when SVVYGLR and SVVYGL peptides were coated 
onto the wells, FLS adhered to SVVYGLR peptide, but not SVVYGL in a dose-
dependent manner (Fig. 9C). 
FIGURE 9. Preferential adhesion of fibroblast-Like synoviocytes (FLS) to thrombin-
cleaved OPN (OPN-R) 
A, Fluorescently labeled fibroblast-like synoviocytes adhesion to WT OPN-F1, OPN-R, 
OPN-L, RGD mutated OPNs (indicated as RAA-FL, RAA-R, and RAA-L), and BSA 
coated wells. Data representative of four experiments with n = 8. B, Fluorescently 
labeled FLS adhesion to RGDS (avP3 integrin binding site) coated wells in a dose-
dependent manner. C, FLS adhesion to SVVYGLR (oupi integrin binding site) coated 
wells in a dose-dependent manner. B & C, Data representative of two experiments with 
n=6. 
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Discussion 
The hypothesis that prompted this study was the premise that thrombin cleavage 
of OPN plays a role in the pathophysiology of RA, and that cleavage of OPN-R by CPB 
may down regulate the role OPN-R plays in rheumatoid arthritis. Recent studies have 
reported increased OPN levels in the RA synovial fluids (9, 10). Ohshima et al. also 
reported presence of cleaved forms of OPN in RA synovial fluids using an indirect 
ELISA method (10). They compared binding of an antibody that recognizes both intact 
and cleaved forms of OPN to one which recognizes intact OPN only, in order to deduce 
the level of thrombin-cleaved OPN is high in RA compared to osteoarthritis. On the 
contrary, the OPN-R and OPN-L ELISA described in this study directly detect the 
thrombin-cleaved and the thrombin / CPB-cleaved osteopontin in biological fluids and 
can distinguish these forms from the MMP3 and MMP7-cleaved products. 
Extensive characterization of the two antibodies, Anti-OPN-R and Anti-OPN-L, 
by Western blot (Fig. 4) and ELISA (Fig. 5 and Fig. 6) is indicative of the specificity of 
the antibodies for their respective antigens. Epitope mapping of OPN-R antibodies 
revealed that Anti-OPN-R, which was raised against SLAYGLR peptide, specifically 
binds to the four amino acids YGLR. On the other hand, Anti-OPN-L raised against 
SVVYGL recognizes the first valine and the YGL sequence. The fact that the C-terminal 
residues N-terminal to the thrombin / CPB cleavage site, namely leucine (in the case of 
Anti-OPN-L) and arginine (in the case of Anti-OPN-R) and their carboxyl groups are 
essential for antibody recognition (Fig. 7), confirm that the antibodies would not 
recognize MMP3 and MMP9-cleaved OPN. Since the two metalloproteinases are known 
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to cleave after glycine within the SVVYGLR sequence, cleavage with these 
metalloproteinases essentially destroys the Anti-OPN-R and Anti-OPN-L recognition 
sites. It should be noted, even though Anti-OPN-R and Anti-OPN-L specifically 
recognize the thrombin-cleaved and thrombin / CPB-cleaved OPN, they cannot 
distinguish whether these cleaved forms of OPN have been further cleaved by other 
proteases. 
Once specificity of the antibodies were determined, they were used to investigate 
whether OPN-R and OPN-L could be detected from the RA synovial fluids. Synovial 
fluid OPN has not been characterized, but it is known that the protein is highly modified 
post-translationally. Therefore, it could be speculated that the glycosylation and 
phosphorylation patterns of OPN found in synovial fluid would be different from milk 
OPN and could possibly contribute to differential affinities of the antibodies for the two 
forms. Therefore, the initial attempt was to analyze the synovial fluid OPN by Western 
blot. However, due to the presence of high concentrations of albumin, immunoglobulins 
and rheumatoid factor in the synovial fluid samples which non-specifically reacted with 
the antibodies, Western blot analysis of synovial fluid OPN failed. Therefore, sandwich 
ELISA was used as the method of choice, to minimize non-specific interactions. In this 
way only osteopontin would bind to the Anti-OPN capture antibody on the plate and all 
else would be washed away, therefore, the chance of cross-reactivity with antibodies 
were minimized. However, in a Western blot setting where whole synovial fluid is run on 
a gel and all proteins are transferred onto a blot the chance of non-specific interactions 
are considerably higher. 
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Using the specific OPN-R and OPN-L ELISA, levels of both OPN-R and OPN-L 
were found to be significantly elevated within the rheumatic joints compared to their 
levels in OA and PsA joints, supporting the notion that thrombin cleavage of OPN and 
the subsequent cleavage of OPN-R into OPN-L by CPB occur within the rheumatic 
joints. 
There was a wide range of full-length and cleaved OPN levels in the synovial 
fluids of RA patients compared to OA and PsA, ranging from undetectable to more than 
50 ug/ml (Fig. 8A). Such wide distribution of OPN level may be partly attributed to 
stage of disease, its severity, and the particular treatment regimen at time of synovial 
fluid collection. Therefore, further studies of the inflammatory state of the patients are 
necessary to understand the heterogeneity of OPN levels found in RA. 
Contrary to previous published results (10), in this study the median OPN-FL 
level of RA synovial fluids was not significantly higher compared to OA and PsA 
(Fig. 8A). This finding may be partly explained by the small sample size, or by variations 
in the inflammatory stage of disease and treatment regimens of individual patients at time 
of fluid collection. 
The ratio of cleaved OPNs (OPN-R and OPN-L) to OPN-FL in RA synovial fluid 
samples had a median value of 0.5, suggesting that almost half of the OPN within the 
rheumatic joint space has been cleaved into OPN-R and OPN-L (Fig. 8B). On the 
contrary, the ratio of cleaved OPNs to OPN-FL in OA and PsA was significantly lower. 
This finding is suggestive that the cleaved forms of OPN may play important roles in the 
pathogenesis of RA, but not OA and PsA. 
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Once it was established that cleaved OPNs are present at high levels in at least a 
subset of RA synovial fluids, the biological relevance of this finding was explored using 
cells from RA joints. The primary fibroblast-like synoviocytes (FLS) within the joint 
space express a4 (CD49d) on their surface (23). On the other hand, thrombin-exposed C-
terminal sequence SVVYGLR of OPN-R binds to the a4 subunit of a4(31 (18). 
Furthermore, data on integrin profile of fibroblast-like synoviocytes showed there is a 3-4 
fold increased expression of cc4 in rheumatoid arthritic synovium compared to normal 
synovium (23). This information along with the finding that FLS binds OPN-R 
preferentially when compared to OPN-FL and the doubly-cleaved OPN-L (Fig. 9A), 
suggest thrombin-cleaved form of osteopontin may be biologically active in rheumatoid 
arthritis. While OPN-R was able to support substantial cell binding, adhesion to OPN-L 
was reduced to levels seen with OPN-FL, suggesting that in vivo CPB conversion of 
OPN-R into OPN-L, may possibly serve as a regulator of integrin-mediated cell adhesion 
to OPN-R. Although the present study is suggestive that OPN-R has a possible role in 
the pathogenesis of RA, further studies are needed to investigate the specific nature of the 
interaction of OPN-R with the fibroblast-like synoviocytes within the joint space and the 
role OPN-R may play in the progression of rheumatoid arthritis. In addition, the cleaved 
OPN ELISA systems developed for this study may serve as an effective tool for studying 
thrombin-cleaved OPN and thrombin / CPB-cleaved OPN levels in different 
inflammatory conditions. 
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